The sodium-glucose cotransporter-2 (SGLT2) inhibitor DWP16001 is a new drug for treatment of type 2 diabetes, developed by Daewoong Pharmaceutical Co., Ltd (Seoul, Republic of Korea), and is currently undergoing a Phase 3 clinical trial in Korea (Registration No. NCT04632862) after getting promising outcome at Phase 2 clinical trial (Registration No. NCT04014023) [14]. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.